Profund Advisors LLC Has $2.23 Million Position in Protagonist Therapeutics, Inc. $PTGX

Profund Advisors LLC increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 40.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,574 shares of the company’s stock after acquiring an additional 7,417 shares during the quarter. Profund Advisors LLC’s holdings in Protagonist Therapeutics were worth $2,234,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PTGX. ProShare Advisors LLC boosted its stake in Protagonist Therapeutics by 6.8% in the 4th quarter. ProShare Advisors LLC now owns 14,084 shares of the company’s stock valued at $1,230,000 after purchasing an additional 897 shares during the period. Abacus Wealth Partners LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter worth $329,000. AIHC Capital Management Ltd acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter worth $16,579,000. Oregon Public Employees Retirement Fund grew its holdings in shares of Protagonist Therapeutics by 1.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock worth $1,170,000 after purchasing an additional 193 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in shares of Protagonist Therapeutics by 62.8% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,400 shares of the company’s stock worth $2,218,000 after purchasing an additional 9,800 shares in the last quarter. 98.63% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 15,000 shares of the business’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $104.79, for a total transaction of $1,571,850.00. Following the sale, the insider directly owned 84,115 shares in the company, valued at approximately $8,814,410.85. The trade was a 15.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Asif Ali sold 1,750 shares of the business’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $105.47, for a total value of $184,572.50. Following the sale, the chief financial officer owned 59,003 shares in the company, valued at approximately $6,223,046.41. The trade was a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 254,345 shares of company stock valued at $25,810,506. 5.19% of the stock is currently owned by insiders.

Protagonist Therapeutics Trading Down 2.4%

Shares of Protagonist Therapeutics stock opened at $98.37 on Wednesday. The business’s fifty day simple moving average is $101.04 and its 200 day simple moving average is $90.89. The firm has a market capitalization of $6.33 billion, a P/E ratio of -54.35 and a beta of 1.89. Protagonist Therapeutics, Inc. has a 12 month low of $44.72 and a 12 month high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. Analysts predict that Protagonist Therapeutics, Inc. will post 2.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on PTGX. Jefferies Financial Group restated a “buy” rating and set a $121.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $110.00 target price on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. HC Wainwright increased their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Truist Financial increased their price target on Protagonist Therapeutics from $110.00 to $121.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. Finally, Wedbush raised their target price on Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $113.69.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.